Drug Profile
RM 853
Alternative Names: RM-853; T-3525770Latest Information Update: 28 May 2022
Price :
$50
*
At a glance
- Originator Takeda
- Developer Rhythm; Takeda
- Class Obesity therapies
- Mechanism of Action Ghrelin O-acyltransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Prader-Willi syndrome
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Prader-Willi-syndrome in USA (PO)
- 31 Dec 2020 Rhythm Pharmaceuticals in-licenses patent family from Takeda, prior to December 2020
- 31 Dec 2020 Rhythm has patent protection for composition of matter and methods of use of RM 853 in USA and other countries, including China, Europe, and Japan, prior to December 2020